



Original Article

Management Protocols of stable coronary artery disease in India: Executive summary



Sundeep Mishra^{a,*}, Saumitra Ray^b, Jamshed J. Dalal^c, J.P.S. Sawhney^d, S. Ramakrishnan^a, Tiny Nair^e, S.S. Iyengar^f, Vinay K. Bahl^a

^a Department of Cardiology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India

^b AMRI Hospital, Kolkata, India

^c Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

^d Department of Cardiology, Sir Ganga Ram Hospital, New Delhi, India

^e PRS Hospital, Trivandrum, India

^f Consultant Cardiologist, Manipal Hospital, Bangalore, India

1. Introduction

In the last three decades, the prevalence of coronary artery disease (CAD) has increased from 1.1% to about 7.5% in the urban population and from 2.1% to 3.7% in the rural population.¹ Coronary artery disease tends to occur at a younger age in Indians with 50% of cardiovascular (CV) mortality occurring in individuals aged less than 50 years.^{2,3}

In a view of high prevalence of CAD in India there is a need for cardiologists' even physicians' to be updated on the recent developments in diagnosis and treatment. However, currently every clinician is inundated with numerous data (for which he/she may have not have sufficient time to go through). Herein clinical guidelines provide a quick solution for day-to-day problems and assist physicians, particularly cardiologists, in clinical decision-making by delineating a gamut of commonly acceptable modalities for the diagnosis, management, and prevention of stable CAD (SCAD). On the other hand guidelines by themselves may have several limitations; they are generally developed based on practice in West (which might be different in developing world), they are too many, and they may be difficult to understand by an average physician. In this context practice standards and management algorithms may offer better guidance to a practicing physician.

The current practice standard has defined practices that meet the needs of most patients in the Indian context. A modified GRADE system was used to derive quality of evidence as 1 (high-quality evidence from consistent results of well-performed randomised trials), 2 (moderate quality evidence from randomised trials), 3 (low-quality evidence from observational studies), or 4 (practice point). The strength of recommendations was categorised as either A ("RECOMMENDED", strong recommendation) or B ("SUGGESTED", weak recommendation).

2. Diagnosis

- Patient's history and physical examination should be considered to identify all the symptoms and signs of CV disease, CV risk factors, and other cardiac aetiologies. (Grade A, Evidence level 3)^{4,5}
- The basic first-line testing in patients with suspected SCAD includes standard laboratory biochemical testing (including haemoglobin, glycated haemoglobin [HbA1c], lipid profile, liver, renal and thyroid function tests), a resting ECG, resting echocardiography and, a chest X-ray. (Grade A, Evidence level 3)^{6–11}
- It is recommended to include assessment of resting heart rate in SCAD patients as a routine clinical practice. (Grade A, Evidence level 2)^{12–14}
- Exercise electrocardiogram testing, if possible, should be preferred in patients with a pre-test probability (based on character of symptom, age and sex) of 15–65% as it is more relevant to their activities than pharmacological testing. (Grade A, Evidence level 2)^{15,16}
- In patients who cannot exercise to an adequate workload, pharmacological testing with adenosine-induced vasodilator perfusion imaging or dobutamine echocardiography should be considered. (Grade A, Evidence level 4)⁶
- An invasive coronary angiogram is indicated in significantly symptomatic patients and patients with high risk features on non-invasive testing. [Grade A, Evidence 4]
- Certain specific types of angina (microvascular, vasospastic and silent angina) should be diagnosed by a combination of available diagnostic techniques and should be individualised. (Grade A, Evidence level 4)⁶

3. Lifestyle management and control of risk factors

- It is recommended to stop all forms of tobacco (smoking and smokeless) for the prevention and control of cardiovascular risk. (Grade A, Evidence level 1)^{17–20}
- Patients with previous acute myocardial infarction, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), stable angina pectoris, or stable chronic heart failure

* Corresponding author.

E-mail address: sundeepmishrai@jagmail.com (S. Mishra).

should undergo moderate-to-vigorous intensity aerobic exercise training ≥ 3 times a week and 30 min per session. Sedentary patients should be strongly encouraged to start light-intensity exercise programmes after adequate exercise-related risk stratification. (Grade A, Evidence level 3)²¹

- Weight reduction in overweight and obese people is recommended to have favourable effects on blood pressure and dyslipidaemia, which may lead to less CVD. (Grade A, Level 1). More precisely, it is recommended to attain BMI < 22.9 kg/m² and WC (Men: 90 cm; women: 80 cm) to minimise the cardiovascular risk. [Grade A, evidence 1]^{50,58–61}
- All the SCAD patients should be treated with statins to achieve optimal LDL-C goal < 70 mg/dl. [Grade A, Evidence 2]^{27–30}
- All the SCAD patients with hypertension should be recommended to attain systolic blood pressure/diastolic blood pressure goal of 140/90 mmHg and in diabetes 140/85 mmHg with medical management. (Grade A, Evidence level 2)^{31–36}
- HbA_{1c} of $< 7.0\%$ should be the objective while treating SCAD patients with diabetes. (Grade A, Evidence level 2)^{37–39}

4. Pharmacological management (Fig. 1)

- Short-acting nitrates are indicated for the immediate relief of anginal symptoms (Grade A, Evidence level 2)^{6,40,41}
- β -Blockers and/or calcium channel blockers are the initial agents for long-term symptom management and heart rate control based on co-morbidities, contra-indications and patient preference. (Grade A, Evidence level 1)^{6,42–44}
- The combination of nondihydropyridine calcium channel blocker with β -blockers should be avoided in patients with anticipated risk of atrioventricular block or severe bradycardia. (Grade A, Evidence level 4)^{45,46}
- The addition of long-acting nitrates or trimetazidine or ivabradine or ranolazine or nicorandil is proposed in case of intolerance or contra-indications or failure in achieving angina control by β -blockers and/or calcium channel blockers. The choice of the drug should be made on the basis of blood pressure, heart rate and tolerance. (Grade A, Evidence level 2)^{47–54}
- Ivabradine may be considered in symptomatic patients who do not tolerate beta-blockers or in whom the resting heart rate remains above 70 bpm, despite administration of the full tolerable dose of beta-blockers. [Grade: A, Evidence: 2]^{51,55,56}
- When two haemodynamically acting drugs fail to achieve the desired results in reducing angina, preference may be given to cardio-metabolic agents like trimetazidine or ranolazine which has a different mode of action and offers better efficacy in combination with a haemodynamic agent. (Grade A, Evidence level 2)^{57,58}

5. Event prevention (Fig. 2)

- Indefinite daily low-dose aspirin is recommended in all SCAD patients if not contraindicated. (Grade A, Evidence level 1)^{59–61}
- Clopidogrel is recommended in patients with aspirin intolerance. (Grade A, Evidence level 2)^{62–65}
- In view of absence of any trial showing the benefit of prasugrel or ticagrelor in stable angina patients and also considering their cost in this sub-set of patients, they may be avoided pending results of the trials addressing this issue. [Grade A, Evidence 4]
- Statin should be prescribed in all patients with SCAD irrespective of lipid levels. (Grade A, Evidence level 2)⁶⁶
- All stable angina patients with diabetes, hypertension, heart failure or early chronic kidney disease should be recommended

to receive angiotensin converting enzyme (ACE) inhibitors if not contra-indicated. (Grade A, Evidence level 1)^{67–70}

- Rest of the patients with SCAD should also be recommended to receive ACE inhibitors. (Grade A, Evidence level 2)^{69–71}
- A combination of ACE inhibitors and amlodipine may be considered in hypertensive CAD patients for improving CV outcomes. (Grade A, Evidence level 2)^{72–74}
- Angiotensin receptor blockers treatment may be used as an alternative therapy for patients who are intolerant to ACE inhibitors. (Grade A, Evidence level 2)^{75,76}

6. Treatment of certain forms of SCAD

6.1. Silent myocardial ischaemia

- Silent myocardial ischaemia should be managed in the similar lines as symptomatic stable angina and needs administration of anti-ischaemic therapy and revascularisation as required. (Grade A, Evidence level 4)⁶
- Use of optimal medical therapies such as lipid-lowering agents, β -blockers and metabolic therapies such as trimetazidine or ranolazine can be prescribed after careful examination of the patient according to the individual on a case to case basis. (Grade A, Evidence level 3)^{77–80}

6.2. Microvascular angina

- Microvascular angina patients can be initially treated with β -blockers in addition to secondary preventive agents including aspirin and statins. (Grade A, Evidence level 3)^{81–83}
- Calcium channel blockers can be prescribed if β -blockers are inadequate or not tolerated in microvascular angina. (Grade A, Evidence level 3)^{84–86}
- Novel agents like trimetazidine, ranolazine and ivabradine may be effective in microvascular angina. (Grade A, Evidence level 3)^{87–89}

6.3. Vasospastic angina


- The treatment of vasospastic angina should be individualised according to the diagnosis of each case. (Grade A, Evidence level 4)⁶
- Calcium channel blockers can be used for effective prevention of vasospastic angina. (Grade A, Evidence level 3)^{6,90,91}
- In patients who continue to be symptomatic agents like trimetazidine, nicorandil, ranolazine and ivabradine may be effective. [Grade A, Evidence 3]

6.4. Revascularisation

- The decision of considering revascularisation in patient with SCAD should be individualised. Revascularisation can be opted early when patients symptoms are uncontrolled by medical therapy alone and/or have high-risk features. (Grade A, Evidence level 4)⁶
- While selecting whether PCI or CABG for revascularisation, the decision should be purely individualised and consensus based. (Grade A, Evidence level 4)⁶

The management algorithm of stable coronary artery disease is given in Fig. 1A & B.

A



B




Fig. 1. An algorithm for pharmacological management and event prevention. (A) Pharmacological management and event prevention. (B) Medical management options. *Abbreviations:* SCAD, stable coronary artery disease; CT, computed tomographic; ECG, electrocardiogram; LAD, left anterior descending; TVD, triple vessel disease; LV, left ventricular; SVD, single vessel disease; DVD, double vessel disease; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; EF, ejection fraction; ASA, acetyl salicylic acid (aspirin); ACEIs, angiotensin-converting-enzyme inhibitors; ARB, angiotensin receptor blocker; BBs, beta-blockers; CCBs, calcium channel blockers; DHP, Dihydropyridine; HR, heart rate; BP, blood pressure.




Fig. 2. Management of special type of angina. (A) Management of stable angina. (B) Management of microvascular angina. (C) Management of vasospastic angina. Abbreviations: PET, positron emission tomography; CMR, cardiovascular magnetic resonance; ECG, electrocardiogram.

The management algorithm of silent myocardial ischaemia, microvascular angina and vasospastic angina is given in Fig. 2A, B & C, respectively.

7. Treatment of special groups of population

7.1. Diabetes

- An objective for HbA_{1c} of <7.0% and blood pressure <140/85 mmHg is recommended for the prevention of microvascular disease in diabetic patients. (Grade A, Evidence level 2)^{31,32,37,38}
- All SCAD patients with diabetes should be recommended to receive an aspirin, high intensity statin and ACE inhibitor or a combination of ACE inhibitor with diuretic if not contraindicated. [Grade A, Evidence 1]^{21,92,101}
- For symptomatic treatment of SCAD patients with diabetes, long-acting nitrates or trimetazidine or ivabradine or ranolazine or nicorandil may be considered the first choice as beta-blockers are contra-indicated. (Grade A, Evidence level 3)^{93,94}
- Trimetazidine is particularly beneficial in diabetic multivessel coronary artery disease patients who may also have diffused vessel disease. (Grade A, Evidence level 3)⁹³
- All SCAD patients with diabetes should be treated with Oral Antidiabetics (OADs) which have shown CV safety/benefits such as metformin, gliclazide, gliptins, SGLT2 inhibitors (empagliflozin). (Grade A, Evidence level 2)^{95–99}
- Revascularisation is recommended in diabetic patients, with persistent symptoms despite optimal medical therapy or high risk features on non-invasive testing. [Grade A, Evidence 4]^{6,100}
- PCI may be considered in single vessel disease and select cases of multi-vessel disease in consultation with heart team. [Grade A, Evidence 4]^{6,100}
- Coronary artery bypass grafting can be recommended in high-risk diabetic patients with multi-vessel disease, left main coronary artery disease or in the presence of LV dysfunction. [Grade A, Evidence 4]^{6,100}

7.2. Chronic kidney disease

- All stable angina patients with chronic kidney disease should be recommended to receive optimal medical therapy. ACE inhibitors can be used if not contra-indicated with careful monitoring of serum creatinine and potassium levels. (Grade A, Evidence level 4)³⁶

Conflicts of interest

The authors have none to declare.

References

1. Sharma R, Bhairappa S, Prasad S, et al. Clinical characteristics, angiographic profile and in hospital mortality in acute coronary syndrome patients in south Indian population. *Heart India*. 2014;2(3):65–69.
2. Nag T, Ghosh A. Cardiovascular disease risk factors in Asian Indian population: a systematic review. *J Cardiovasc Dis Res*. 2013;4(4):222–228.
3. Dalal J, Hiremath MS, Das MK, et al. Vascular disease in young Indians (20–40 years): role of ischemic heart disease. *J Clin Diagn Res*. 2016;10(9):OE08–OE12.
4. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. *Ann Intern Med*. 1993;118(2):81–90.
5. Mancini GB, Gosselin G, Chow B, et al. Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. *Can J Cardiol*. 2014;30(8):837–849.
6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. *Eur Heart J*. 2013;34(38):2949–3003.
7. da Silveira AD, Ribeiro RA, Rossini AP, et al. Association of anemia with clinical outcomes in stable coronary artery disease. *Coron Artery Dis*. 2008;19:21–26.
8. Schwarz PE, Li J, Lindstrom J, Tuomilehto J. Tools for predicting the risk of type 2 diabetes in daily practice. *Horm Metab Res*. 2009;41:86–97.
9. Di Angelantonio E, Danesh J, Eiriksdottir G, et al. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. *PLoS Med*. 2007;4:e270.

10. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2013;34(39):3035–3087.
11. Bartnik M, Rydén L, Malmberg K, et al. Euro Heart Survey I. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. *Heart*. 2007;93:72–77.
12. Ruiz Ortiz M, Romo E, Mesa D, et al. Prognostic value of resting heart rate in a broad population of patients with stable coronary artery disease: prospective single-center cohort study. *Rev Esp Cardiol Engl Ed*. 2010;63(11):1270–1280.
13. Diaz A, Bourassa MG, Guertin MC, et al. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. *Eur Heart J*. 2005;26(10):967–974.
14. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. *Eur Heart J*. 2005;26(10):943–945.
15. Gianrossi R, Detrano R, Mulvihill D, et al. Exercise-induced ST depression in the diagnosis of coronary artery disease. A meta-analysis. *Circulation*. 1989;80:87–98.
16. Shaw LJ, Mieres JH, Hendel RH, et al. Comparative effectiveness of exercise electrocardiography with or without myocardial perfusion single photon emission computed tomography in women with suspected coronary artery disease: results from the What is the Optimal Method for Ischemia Evaluation in Women (WOMEN) trial. *Circulation*. 2011;124:1239–1249.
17. He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. *N Engl J Med*. 1999;340(12):920–926.
18. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. *BMJ*. 2009;339:b3060.
19. Gupta R, Gupta N, Khedar RS. Smokeless tobacco and cardiovascular disease in low and middle income countries. *Indian Heart J*. 2013;65(4):369–377.
20. Fischer F, Kraemer A. Meta-analysis of the association between second-hand smoke exposure and ischaemic heart diseases. COPD and stroke. *BMC Public Health*. 2015;15:1202.
21. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J*. 2012;33(13):1635–1701.
22. Misra A, Chowbey P, Makkar BM, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. *J Assoc Physicians India*. 2009;57:163–170.
23. Dudeja V, Misra A, Pandey RM, et al. BMI does not accurately predict overweight in Asian Indians in northern India. *Br J Nutr*. 2001;86(1):105–112.
24. Misra A, Pandey RM, Sinha S, et al. Receiver operating characteristics curve analysis of body fat & body mass index in dyslipidaemic Asian Indians. *Indian J Med Res*. 2003;117:170–179.
25. Vikram NK, Misra A, Pandey RM, et al. Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard. *Diabetes Nutr Metab*. 2003;16:32–40.
26. Singh KD, Dhillon JK, Arora A, Gill BS. Receiver operating characteristic curve analysis of BMI and percentage body fat in type 2 diabetics of Punjab. *Indian J Physiol Pharmacol*. 2004;48(1):73–80.
27. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366(9493):1267–1278.
28. Ebrahimi R, Saleh J, Toggart E, et al. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis. *J Invasive Cardiol*. 2008;20(6):292–295.
29. Dorresteijn JA, Boekholdt SM, van der Graaf Y, et al. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. *Circulation*. 2013;127(25):2485–2493.
30. Enas EA, Kuruvila A, Khanna P, et al. Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians – a population with the highest risk of premature coronary artery disease & diabetes. *Indian J Med Res*. 2013;138(4):461–491.
31. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. *Lancet*. 1998;351:1755–1762.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703–713.
33. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. *J Hypertens*. 2009;27:923–934.
34. Liu L, Zhang Y, Liu G, et al. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. *J Hypertens*. 2005;23:2157–2172.
35. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. *Lancet*. 2004;363:2049–2051.
36. Bicket DP. Using ACE inhibitors appropriately. *Am Fam Physician*. 2002;66(3):461–468.
37. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonyl ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*. 1998;352:837–853.
38. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358:2560–2572.
39. Piepoli MF, Hoes AW, Agewall S, et al. Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016;37(29):2315–2381.
40. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. *Lancet*. 1995;345(March (8951)):669–685.
41. Savonitto S, Motolese M, Agabiti-Rosei E. Antianginal effect of transdermal nitroglycerin and oral nitrates given for 24 hours a day in 2,456 patients with stable angina pectoris. The Italian Multicenter Study. *Int J Clin Pharmacol Ther*. 1995;33(4):194–203.
42. Davies RF, Habibi H, Klink WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. *J Am Coll Cardiol*. 1995;25:619–625.
43. Klein WW, Jackson G, Tavazzi L. Efficacy of monotherapy compared with combined antianginal drugs in the treatment of chronic stable angina pectoris: a meta-analysis. *Coron Artery Dis*. 2002;13(8):427–436.
44. Mishra S. Does modern medicine increase life-expectancy: Quest for the Moon Rabbit? *Indian Heart J*. 2016;68:19–27.
45. Mills TA, Kawji MM, Cataldo VD, et al. Profound sinus bradycardia due to diltiazem, verapamil, and/or beta-adrenergic blocking drugs. *J La State Med Soc*. 2004;156(6):327–331.
46. Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. *J Am Coll Cardiol*. 2004;44(1):105–108.
47. Thadani U, Fung HL, Darke AC, et al. Oral isosorbidedinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. *Am J Cardiol*. 1982;49:411–419.
48. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. *Am J Cardiol*. 1993;72:1249–1256.
49. de Vries RJ, Dunselman PH, van Veldhuisen DJ, et al. Comparison between felodipine and isosorbide mononitrate as adjunct to beta blockade in patients > 65 years of age with angina pectoris. *Am J Cardiol*. 1994;74(12):1201–1206.
50. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil Angina (IONA) randomised trial. *Lancet*. 2002;359:1269–1275.
51. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. *Eur Heart J*. 2005;26:2529–2536.
52. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. *Eur Heart J*. 2009;30:540–548.
53. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Segment Elevation Acute Coronary Syndromes) 36 Trial. *J Am Coll Cardiol*. 2009;53:1510–1516.
54. National Clinical Guidelines Centre. *Stable Angina: Management. Clinical guideline [CG126]*. 2011 Available from: <https://www.nice.org.uk/guidance/cg126/evidence/full-guideline-183176605>. [accessed 07.11.16].
55. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. *Lancet*. 2008;372(9641):817–821.
56. Amosova E, Andrejev E, Zaderey I, et al. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. *Cardiovasc Drugs Ther*. 2011;25(6):531–537.
57. Jackson G. Combination therapy in angina: a review of combination haemodynamic treatment and the role of combined haemodynamic and cardio-metabolic agents. *Int J Clin Pract*. 2001;55(4):256–261.
58. Chazov E, Lepakchin V, Zharova E, et al. Trimetazidine in Angina Combination Therapy—the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study. *Am J Ther*. 2005;12(1):35–42.
59. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. *BMJ*. 2002;324:71–86.
60. Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. *Lancet*. 1992;340:1421–1425.
61. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. *Am J Med*. 2008;121(1):43–49.

62. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet*. 1996;348(9038):1329–1339.
63. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. *Circulation*. 2001;103(3):363–368.
64. Ringleb PA, Bhatt DL, Hirsch AT, et al. Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. *Stroke*. 2004;35(2):528–532.
65. Schiano P, Steg PG, Barbou F, et al. A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. *Eur Heart J Acute Cardiovasc Care*. 2012;1(1):75–78.
66. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *J Am Coll Cardiol*. 2006;48(3):438–445.
67. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med*. 1991;325:293–302.
68. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med*. 1992;327:669–677.
69. Yusuf S, Sleight P, Pogue J, et al. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med*. 2000;342:145–153.
70. Fox KM. EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003;362(9386):782–788.
71. Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, et al. Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials. *J Am Coll Cardiol*. 2006;47(8):1576–1583.
72. Bertrand ME, Ferrari R, Remme WJ, et al. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. *Am Heart J*. 2010;159(5):795–802.
73. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multi-centre randomised controlled trial. *Lancet*. 2005;366(9489):895–906.
74. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*. 2008;359(23):2417–2428.
75. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358(15):1547–1559.
76. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multi-centre, randomised, double-blind, controlled trial. *Lancet*. 2008;372(9638):547–553.
77. Kuralay E, Demirkiliç U, Özal E, et al. Myocardial ischemia after coronary bypass: comparison of Trimetazidine and Diltiazem. *Asian Cardiovasc Thorac Ann*. 1999;7(2):84–89.
78. Kikalishvili TT, Chumburidze VB, Kurashvili RB, et al. P-459: exercise-induced and silent ischemia: different effects of monotherapy. *Am J Hypertens*. 2001;14(S1):185A.
79. Marazzi G, Wajngarten M, Vitale C, et al. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. *Int J Cardiol*. 2007;120(1):79–84.
80. Xu X, Zhang W, Zhou Y, et al. Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up. *Clin Drug Investig*. 2014;34(4):251–258.
81. Bugiardini R, Borghi A, Biagetti L, et al. Comparison of verapamil versus propranolol therapy in syndrome X. *Am J Cardiol*. 1989;63(5):286–290.
82. Lanza GA, Colonna G, Pasceri V, et al. Atenolol versus amlodipine versus isorbide-5-mononitrate on anginal symptoms in syndrome X. *Am J Cardiol*. 1999;84(7):854–856.
83. Marinescu MA, Loffler AI, Ouellette M, et al. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. *JACC Cardiovasc Imaging*. 2015;8(2):210–220.
84. Cannon CR, Watson RM, Rosing DR, et al. Efficacy of calcium channel blocker therapy for angina pectoris resulting from small-vessel coronary artery disease and abnormal vasodilator reserve. *Am J Cardiol*. 1985;56(4):242–246.
85. Ozcelik F, Altun A, Ozbay G. Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X. *Clin Cardiol*. 1999;22(5):361–365.
86. Wang L, Cheng Z, Gu Y, et al. Short-term effects of verapamil and diltiazem in the treatment of no reflow phenomenon: a meta-analysis of randomized controlled trials. *Biomed Res Int*. 2015;2015:382086.
87. Nalbantgil S, Altintigil A, Yilmaz H, et al. The effect of trimetazidine in the treatment of microvascular angina. *Int J Angiol*. 1999;8(1):40–43.
88. Rogacka D, Guzik P, Wykretowicz A, et al. Effects of trimetazidine on clinical symptoms and tolerance of exercise of patients with syndrome X: a preliminary study. *Coron Artery Dis*. 2000;11(2):171–177.
89. Villano A, Di Franco A, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. *Am J Cardiol*. 2013;112(1):8–13.
90. Sueda S, Kohno H, Fukuda H, et al. Limitations of medical therapy in patients with pure coronary spastic angina. *Chest*. 2003;123:380–386.
91. Guidelines for diagnosis and treatment of patients with vasospastic angina (coronary spastic angina) (JCS 2008): digest version. *Circ J*. 2010;74:1745–1762.
92. Investigators HOPE. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet*. 2000;355(9200):253–259.
93. Belardinelli R, Cianci G, Gigli M, et al. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy. *J Cardiovasc Pharmacol*. 2008;51:611–615.
94. Shehata M. Cardioprotective effects of oral nicorandil use in diabetic patients undergoing elective percutaneous coronary intervention. *J Interv Cardiol*. 2014;27(5):472–481.
95. Lavrenko AV, Kutsenko LA, Solokhina IL, et al. [Efficacy of metformin as initial therapy in patients with coronary artery disease and diabetes type 2]. *Lik Sprava*. 2011;(1–2):89–95.
96. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. *Eur Heart J*. 2013;32(15):1900–1908.
97. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. *Diabetes Care*. 2013;36(5):1304–1311.
98. Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*. 2016;374(11):1094.
99. White WB, Cannon CP, Heller SR, et al. EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. *N Engl J Med*. 2013;369(14):1327–1335.
100. Singh M, Arora R, Kodumuri V, et al. Coronary revascularization in diabetic patients: current state of evidence. *Exp Clin Cardiol*. 2011;16(1):16–22.